Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection. Issue 6 (26th July 2022)

• Record Type: Journal Article
• Authors: Bender Ignacio, Rachel A.; Wohl, David A.; Arends, Rosalin; Pilla Reddy, Venkatesh; Mu, Ying; Javan, Arzhang Cyrus; Hughes, Michael D.; Eron, Joseph J.; Currier, Judith S.; Smith, Davey; Chew, Kara W.; Gibbs, Michael; Fletcher, Courtney V.
• Is Part Of: Clinical pharmacology & therapeutics. Volume 112:Issue 6(2022)
• Page Start: 1207
• Page End: 1213
• Publication Date: 2022-07-26
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2706
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : AZD7442 (Evusheld) is a combination of two human anti‐severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and cilgavimab (AZD1061). Route of administration is an important consideration to improve treatment access. We assessed pharmacokinetics (PKs) of AZD7442 absorption following 600 mg administered intramuscularly (i.m.) in the thigh compared with 300 mg intravenously (i.v.) in ambulatory adults with symptomatic COVID‐19. PK analysis included 84 of 110 participants randomized to receive i.m. AZD7442 and 16 of 61 randomized to receive i.v. AZD7442. Serum was collected prior to AZD7442 administration and at 24 hours and 3, 7, and 14 days later. PK parameters were calculated using noncompartmental methods. Following 600 mg i.m., the geometric mean maximum concentration ( C max ) was 38.19 μg/mL (range: 17.30–60.80) and 37.33 μg/mL (range: 14.90–58.90) for tixagevimab and cilgavimab, respectively. Median observed time to maximum concentration ( T max ) was 7.1 and 7.0 days for tixagevimab and cilgavimab, respectively. Serum concentrations after i.m. dosing were similar to the i.v. dose (27–29 μg/mL each component) at 3 days. The area under the concentration‐time curve (AUC)0–7d geometric mean ratio was 0.9 for i.m. vs. i.v. Participants with higher weight or body mass index were more likely to have lower concentrations with either route. Women appeared to have higher interparticipant variability in concentrations compared with men. The concentrations of tixagevimab and cilgavimab after administration i.m. to the thigh were similar to those achieved with i.v. after 3 days from dosing. Exposure in the i.m. group was 90% of i.v. over 7 days. Administration to the thigh can be considered to provide consistent mAb exposure and improve access.